87679-37-6

• 常用中文名：群多普利
• 常用英文名：Trandolapril
• CAS号：87679-37-6
• 分子式：C₂₄H₃₄N₂O₅
• 分子量：430.537
• 相关类别： 原料药 循环系统用药 抗高血压病药
• 发布时间：2018-08-14 20:27:15
• 更新时间：2024-01-02 15:05:42
• Trandolapril(RU44570)是ACE抑制剂,可作用于高血压。

名称

• 中文名: 群多普利
• 英文名: (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
• 中文别名: (2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-乙氧基甲酰-3-苯基-丙基]氨基]丙酰基]-2,3,3a,4,5,6,7,7a-八氢吲哚-2-甲酸; (3ΑR.7ΑS)-1-[N-[1(S)-乙氧羰基]-3-苯丙基]-(S)-丙氨酰八氢吲哚-2(S)-羧酸; 泉多普利
• 英文别名: Trandolaprilum [Latin]; Preran; Trandolaprilum; (2S,3aR,7aS)-1-[(S)-N-[(S)-1-carboxy-3-phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid 1-ethyl ester; (2S,3aR,7aS)-1-[(2S)-2-{[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid (non-preferred name); Trandolapril; (2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid,form I crystalline polymorph of; Gopten; (3aR,7aS)-1-[N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl]octahydroindole-2(S)-carboxylic acid; Mavik; 1-[2-[(1-ethoxycarbonyl-3-phenylpropyl)amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; (2S,3aR,7aS)-1-[(2S)-2-{[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid; Odrik; Udrik; (2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid; [2S-[1[R*(R*)],2a,3aa,7ab]]-1-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid; MFCD00865776; (2S,3aR,7aS)-1-[(2S)-2-{[(2S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid (non-preferred name); (2S,3aR,7aS)-1-[(2S)-2-{[(2S)-1-Ethoxy-1-oxo-4-phenyl-2-butanyl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid; (3aR,7aS)-1-[N-1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-octahydro-1H-indole-2(S)-carboxylic acid; Odric; (2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid,form II crystalline polymorph of

物化性质

• 密度: 1.2±0.1 g/cm3
• 沸点: 626.0±55.0 °C at 760 mmHg
• 熔点: 122-123°C
• 分子式: C₂₄H₃₄N₂O₅
• 分子量: 430.537
• 闪点: 332.4±31.5 °C
• 精确质量: 430.246765
• PSA: 95.94000
• LogP: 3.97
• 外观性状: 白色粉末
• 蒸汽压: 0.0±1.9 mmHg at 25°C
• 折射率: 1.549
• 储存条件: Room temp
• 分子结构:

  1、 摩尔折射率：116.02

  2、 摩尔体积（cm³/mol）：364.5

  3、 等张比容（90.2K）：963.1

  4、 表面张力（dyne/cm）：48.7

  5、 极化率（10-24cm3）：45.99

• 计算化学:

  1.疏水参数计算参考值（XlogP）:无

  2.氢键供体数量:2

  3.氢键受体数量:6

  4.可旋转化学键数量:10

  5.互变异构体数量:无

  6.拓扑分子极性表面积95.9

  7.重原子数量:31

  8.表面电荷:0

  9.复杂度:634

  10.同位素原子数量:0

  11.确定原子立构中心数量:5

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:0

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:1

• 更多:

  1.性状：无色结晶性固体。

  2.熔点（ºC）：125

生物活性

• 描述: Trandolapril(RU44570)是ACE抑制剂,可作用于高血压。
• 相关类别:
  信号通路 >> 代谢酶/蛋白酶 >> 血管紧张素转换酶(ACE)
  研究领域 >> 心血管疾病
• 参考文献:

  [1]. http://en.wikipedia.org/wiki/Trandolapril

MSDS

Section1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE Product identifiers Product name: Trandolapril CAS-No.: 87679-37-6 Relevant identified uses of the substance or mixture and uses advised against Identified uses: Laboratory chemicals, Manufacture of substances Section2. HAZARDS IDENTIFICATION Classification of the substance or mixture Not a dangerous substance according to GHS. This substance is not classified as dangerous according to Directive 67/548/EEC. Label elements The product does not need to be labelled in accordance with EC directives or respective national laws. Other hazards - none Section3. COMPOSITION/INFORMATION ON INGREDIENTS Substances Synonyms: (2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]- 1-oxopropyl]octahydro-1H-Indole-2-carboxylic acid Mavik Formula: C24H34N2O5 Molecular Weight: 430,54 g/mol ComponentConcentration Trandolapril CAS-No.87679-37-6- Section4. FIRST AID MEASURES Description of first aid measures If inhaled If breathed in, move person into fresh air. If not breathing, give artificial respiration. In case of skin contact Wash off with soap and plenty of water. In case of eye contact Flush eyes with water as a precaution. If swallowed Never give anything by mouth to an unconscious person. Rinse mouth with water. Most important symptoms and effects, both acute and delayed To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. Indication of immediate medical attention and special treatment needed no data available Section5. FIRE-FIGHTING MEASURES Extinguishing media Suitable extinguishing media Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. Special hazards arising from the substance or mixture Carbon oxides, nitrogen oxides (NOx) Precautions for fire-fighters Wear self contained breathing apparatus for fire fighting if necessary. Further information no data available Section6. ACCIDENTAL RELEASE MEASURES Personal precautions, protective equipment and emergency procedures Avoid dust formation. Avoid breathing vapors, mist or gas. Environmental precautions Do not let product enter drains. Methods and materials for containment and cleaning up Sweep up and shovel. Keep in suitable, closed containers for disposal. Reference to other sections For disposal see section 13. Section7. HANDLING AND STORAGE Precautions for safe handling Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire protection. Conditions for safe storage, including any incompatibilities Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Specific end uses no data available Section8. EXPOSURE CONTROLS/PERSONAL PROTECTION Control parameters Components with workplace control parameters Exposure controls Appropriate engineering controls General industrial hygiene practice. Personal protective equipment Eye/face protection Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU). Skin protection Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it. Body Protection Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the specific work-place., The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace. Respiratory protection Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). Section9. PHYSICAL AND CHEMICAL PROPERTIES Information on basic physical and chemical properties a) AppearanceForm: powder b) Odourno data available c) Odour Thresholdno data available d) pHno data available e) Melting/freezing point no data available f) Initial boiling point and no data available boiling range g) Flash pointno data available h) Evaporation rateno data available i) Flammability (solid, gas) no data available j) Upper/lowerno data available flammability or explosive limits k) Vapour pressureno data available l) Vapour densityno data available m) Relative densityno data available n) Water solubilityno data available o) Partition coefficient: n- log Pow: 2,444 octanol/water p) Autoignitionno data available temperature q) Decompositionno data available temperature r) Viscosityno data available s) Explosive propertiesno data available t) Oxidizing propertiesno data available Other safety information no data available Section10. STABILITY AND REACTIVITY Reactivity no data available Chemical stability no data available Possibility of hazardous reactions no data available Conditions to avoid no data available Incompatible materials Strong oxidizing agents Hazardous decomposition products Other decomposition products - no data available Section11. TOXICOLOGICAL INFORMATION Information on toxicological effects Acute toxicity LD50 Oral - rat - > 5.000 mg/kg Skin corrosion/irritation no data available Serious eye damage/eye irritation no data available Respiratory or skin sensitization no data available Germ cell mutagenicity no data available Carcinogenicity IARC:No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC. Reproductive toxicity no data available Specific target organ toxicity - single exposure no data available Specific target organ toxicity - repeated exposure no data available Aspiration hazard no data available Potential health effects InhalationMay be harmful if inhaled. May cause respiratory tract irritation. IngestionMay be harmful if swallowed. SkinMay be harmful if absorbed through skin. May cause skin irritation. EyesMay cause eye irritation. Signs and Symptoms of Exposure To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. Additional Information RTECS: NL6015178 Section12. ECOLOGICAL INFORMATION Toxicity no data available Persistence and degradability no data available Bioaccumulative potential no data available Mobility in soil no data available Results of PBT and vPvB assessment no data available Other adverse effects no data available Section13. DISPOSAL CONSIDERATIONS Waste treatment methods Product Offer surplus and non-recyclable solutions to a licensed disposal company. Contaminated packaging Dispose of as unused product. Section14. TRANSPORT INFORMATION UN-Number ADR/RID: -IMDG: -IATA: - UN proper shipping name ADR/RID: Not dangerous goods IMDG: Not dangerous goods IATA:Not dangerous goods Transport hazard class(es) ADR/RID: -IMDG: -IATA: - Packaging group ADR/RID: -IMDG: -IATA: - Environmental hazards ADR/RID: noIMDG Marine pollutant: noIATA: no Special precautions for users no data available SECTION 15 - REGULATORY INFORMATION N/A SECTION 16 - ADDITIONAL INFORMATION N/A

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : NL6015178 CHEMICAL NAME : 1H-Indole-2-carboxylic acid, octahydro-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)am ino)-1- oxopropyl)-, (2S-(1(R*(R*)),2-alpha,3a-alpha,7a-beta))- CAS REGISTRY NUMBER : 87679-37-6 LAST UPDATED : 199612 DATA ITEMS CITED : 15 MOLECULAR FORMULA : C24-H34-N2-O5 MOLECULAR WEIGHT : 430.60 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 27,195,1996 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1420 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 27,195,1996 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >2 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 27,195,1996 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 3990 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 27,195,1996 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1285 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 27,195,1996 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 3 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 27,195,1996 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 2 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 27,195,1996 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 912 mg/kg/1Y-I TOXIC EFFECTS : Gastrointestinal - ulceration or bleeding from stomach Kidney, Ureter, Bladder - changes primarily in glomeruli Blood - changes in erythrocyte (RBC) count REFERENCE : JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 18(Suppl 1),37,1993 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 2275 mg/kg/91D-I TOXIC EFFECTS : Kidney, Ureter, Bladder - urine volume increased Blood - normocytic anemia Nutritional and Gross Metabolic - changes in sodium REFERENCE : JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 18(Suppl 1),1,1993 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 25 gm/kg SEX/DURATION : male 9 week(s) pre-mating female 2 week(s) pre-mating - 1 week(s) after conception TOXIC EFFECTS : Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 18(Suppl 1),93,1993 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 6300 mg/kg SEX/DURATION : female 14 day(s) pre-mating female 1-7 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death REFERENCE : JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 18(Suppl 1),93,1993 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 3300 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - hepatobiliary system Reproductive - Effects on Newborn - physical REFERENCE : JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 19(Suppl 1),107,1993 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 750 mg/kg SEX/DURATION : female 17-20 day(s) after conception lactating female 21 day(s) post-birth TOXIC EFFECTS : Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) REFERENCE : JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 18(Suppl 1),133,1993 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 330 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 18(Suppl 1),107,1993 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 780 mg/kg SEX/DURATION : female 17-21 day(s) after conception lactating female 1-21 day(s) post-birth TOXIC EFFECTS : Reproductive - Effects on Newborn - behavioral Reproductive - Effects on Newborn - physical REFERENCE : JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 18(Suppl 1),133,1993

安全

• 个人防护装备: Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
• 危险品运输编码: NONH for all modes of transport
• RTECS号: NL6015178

合成路线

上下游产品

上游产品  10
82717-90-6 82717-96-2 98677-37-3 145641-35-6
114192-42-6 82717-97-3 84793-24-8 145438-94-4
881637-74-7 80828-13-3
下游产品  1
82717-96-2

制备

1. 3-氯-N-乙酰丙氨酸甲酯的制备

在反应瓶中加入3-氯丙氨酸甲酯盐酸盐181g91.04mol)、乙酰氯163.9g(2.08mol)和无水甲苯1500ml,搅拌加热至回流,回流反应5h直至反应混合物成清澈溶液.反应毕将反应液浓缩至干,剩余物用乙酸乙酯/石油醚混合溶剂重结晶,得3-氯-N-乙酰丙氨酸甲酯170g,收率91%,mp104ºC.

2. 3-(2-氧代环己基)-N-乙酰丙氨酸甲酯的制备

在反应瓶中加入上步制备的化合物3-氯-N-乙酰丙氨酸甲酯160g(0.89mol)、1-吡咯基环己烷171.9g(1.12mol) 和无水DMF1200ml,混合均匀后,将该混合物于20~25ºC放置3天.反应溶液在高真空下浓缩,剩余物中加水600ml后,用浓盐酸调至pH2.水层用乙酸乙酯提取,合并有机相,用无水Na2SO4干燥,过滤,滤液浓缩得油状物3-(2-氧代环己基)-N-乙酰丙氨酸甲酯粗品220g,收率>100%.直接用于下步反应.

3. 3,3a,4,5,6,7-2H-六氢吲哚-2-羧酸盐酸盐的制备

在反应瓶中加入上步制备的化合物3-(2-氧代环己基)-N-乙酰丙氨酸甲酯220g(约0.90mol)(粗品)和2mol/L盐酸1000ml,搅拌加热至沸回流,搅拌回流反应2H.将反应混合物用乙酸乙酯提取,水溶液相浓缩,残留量的水加入甲苯三次,真空共沸蒸馏除去,得黄色油状物3,3a,4,5,6,7-2H-六氢吲哚-2-羧酸盐酸盐210g,收率>100%,该品冷却静置可结晶固化.

4. DL-2β,3αβ,7αa-八氢吲哚-2-羧酸的制备

在氢化反应瓶中加入上步制备的化合物3,3a,4,5,6,7-2H-六氢吲哚-2-羧酸盐酸盐128g(约0.63mol)、冰乙酸700ml和Pd/C(10%)4g,搅拌下用N2置换瓶中空气3次,用H2置换N2后,通H2常压室温氢化反应.反应毕,过滤掉催化剂,滤液浓缩至干,剩余物加热乙醇500ml溶解,将溶液冷却至-20ºC,化合物DL-2β,3αβ,7αa-八氢吲哚-2-羧酸的异构体(2αβ,3αβ, 7αβ-八氢吲哚羧酸)被沉淀出来,分离后的溶液经浓缩后用异丙醇析晶,过滤,得无色晶体DL-2β,3αβ,7αa-八氢吲哚-2-羧酸280g,mp280ºC

5. DL-2β,3αβ,7αa-八氢吲哚-2-羧酸苄酯盐酸盐的制备

在反应瓶中加入苯甲醇14ml(14.58g,134.84mmol)和亚硫酰氯(SOCl2)1.41ml(2.29g,19.27mmol)冷却至-5ºC~0ºC,再在搅拌下于-10ºC~0ºC加入上步制备的化合物DL-2β,3αβ,7αa-八氢吲哚-2-羧酸1.4g(8.28mmol),加毕,将混合物于0ºC搅拌反应1h.于20~25ºC静置过夜.于50ºC将反应液中苄醇(苯甲醇)在高真空下蒸馏干净,剩余物加二异丙醚捣碎研磨,过滤,得DL-2β,3αβ,7αa-八氢吲哚-2-羧酸苄酯盐酸盐2.5g,收率>100%,该产物为无色晶体(仍系粗品),mp154ºC.可直接用于下步反应.

6. N-(1S-乙氧羰基-3-苯丙基)-S-丙氨酰-2β,3αβ,7αa-八氢吲哚-2-羧酸苄酯的制备

在反应瓶中加入N-(1S-乙氧羰基-3-苯丙基)-S-丙氨酸2.16g(7.74mmol)和无水DMF8.6ml,搅拌悬浮,往该悬浮液加入1-羟基苯并三唑1.06g(7.85mol)、上步制备的化合物DL-2β,3αβ,7αa-八氢吲哚-2-羧酸苄酯盐酸盐2.2g(7.45mol)和N-乙基吗啉1.08ml,搅拌混合,再加入二环己基碳化二亚胺(DCC)1.7g(加DCC时控制内温为0ºC),加毕,在20~25ºC搅拌反应3.5h.反应混合物用乙酸乙酯200ml稀释,将产生的二环己基脲沉淀过滤掉,滤液减压浓缩蒸除溶剂,剩余物加入乙醚溶解,溶液用饱和NaHCO3水溶液洗涤2次,无水Na2SO4干燥,过滤,滤液浓缩后剩余物用硅胶柱色谱分离纯化[洗脱剂:乙酸乙酯/环己烷],经后处理得两部分淡黄色油状物(比率为1:1),各含目的化合物N-(1S-乙氧羰基-3-苯丙基)-S-丙氨酰-2β,3αβ,7αa-八氢吲哚-2-羧酸苄酯的一个异构体[即(2R,3αR, 7αS)-N-(1S-乙氧羰基-3-苯丙基)-S-丙氨酰-2β,3αβ,7αa-八氢吲哚-2-羧酸苄酯和(2S,3αS,7αR)- N-(1S-乙氧羰基-3-苯丙基)-S-丙氨酰-2β,3αβ,7αa-八氢吲哚-2-羧酸苄酯.

7. (2S,3αR,7αS)-1-[(2S)-2-[[(1S)-1-(乙氧羰基)-3-苯基丙基]氨基]-1-氧代丙基]八氢-1H-吲哚-2-羧酸(群多普利)的合成

在氢化反应瓶中加入(2S,3αS,7αR)N-(1S-乙氧羰基-3-苯丙基)-S-丙氨酰-2β,3αβ,7αa-八氢吲哚-2-羧酸苄酯1.7g(3.26mol)、无水乙醇60ml和10%Pd/C催化剂200mg,用N2置换瓶中空气3次#用H2置换N2 3次,于25ºC常压通H2反应2h(搅拌下).反应毕,过滤掉催化剂,滤液浓缩蒸除溶剂,得无色泡沫状物(2S,3αR,7αS)-1-[(2S)-2-[[(1S)-1-(乙氧羰基)-3-苯基丙基]氨基]-1-氧代丙基]八氢-1H-吲哚-2-羧酸(群多普利)1.2g,收率85.7%(将该泡沫状目的物制成盐酸盐可得无色无定形粉末).